ClinicalTrials.gg
Drug

Farletuzumab clinical trials

Also written MORAb-003.

studies test it
9
open now
0
in phase 3
1
first study started
2005

How each study uses farletuzumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Farletuzumab
6

Development codes

MORAb-003
7

Studies by the year they started

9 studies that test it; most in 2010 (2)

Studies that test farletuzumab, by start year
YearStudies
20051
20061
20081
20091
20102
20112
20151

By phase

A phase 1/2 study counts in both.

Phase 1
2
Phase 2
6
Phase 3
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 9 · Other 0

Morphotek (7) · Eisai Inc. (1) · Eisai Co., Ltd. (1)

Studies

Open first, then newest update. How each study uses farletuzumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 9

Codes

What other systems call farletuzumab · ClinicalTrials.gg INT005242

  • MeSH (NLM) C527484farletuzumabConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 2O09BG0OWAFARLETUZUMABConfirmed FDA, NLM, Wikidata
  • Wikidata Q3739631farletuzumabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C61503FarletuzumabOne source FDA
  • DrugBank DB05595One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.